June MIMS update

The latest in medicines news from MIMS, with new products, presentations, indications and safety changes New products Loncastuximab tesirine (Zynlonta) is an antibody-drug conjugate (ADC) targeting CD19. The monoclonal immunoglobulin G1 kappa antibody component binds to human CD19, a transmembrane protein expressed on the surface of cells of B-lineage origin. The small molecule component is SG3199,